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Abstract To examine evidence for a role of gluten sensi-
tivity (GS) or celiac disease (CD) in ALS etiology, we
included participants from a population-based case–control
study in The Netherlands between January 2006 and
December 2015. We compared levels and seroprevalence
of IgA antibodies to tissue transglutaminase 6 (TG6) in 359
ALS patients and 359 controls, and to transglutaminase 2
(TG2) and endomysium (EMA) in 199 ALS patients and
199 controls. Questionnaire data on 1829 ALS patients and
3920 controls were examined for CD or gluten-free diets
(GFD). Genetic correlation and HLA allele frequencies
were analyzed using two genome-wide association studies:
one on ALS (12,577 cases, 23,475 controls), and one on
CD (4533 cases, 10,750 controls). We found one patient
with TG6, TG2 and EMA antibodies who had typical ALS
and no symptoms of GS. TG6 antibody concentrations and
positivity, CD prevalence and adherence to a GFD were
similar in patients and controls (p[ 0.66) and in these
patients disease progression was compatible with typical
ALS. CD and ALS were not found to be genetically cor-
related (p[ 0.37). CD-associated HLA allele frequencies
were similar in patients and controls (p[ 0.28). In con-
clusion, we found no serological evidence for involvement
of gluten-related antibodies in ALS etiology nor did we
observe an association between CD and ALS in medical
history or genetic data, indicating that there is no evidence
in our data for an association between the two diseases.
Hence, a role for a GFD in the ALS treatment seems
unlikely.
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Introduction
Recent studies have proposed a potential link between
celiac disease (CD) and ALS [1, 2], and suggest that sen-
sitivity to gluten (GS) may occur in a subgroup of patients,
who may then benefit from a gluten-free diet (GFD) [2].
The efficacy of GFD in seropositive patients is currently
being investigated [3].
These epidemiological observations suggest that CD and
ALS may share (genetic) susceptibility factors. CD has a
clear genetic component (heritability *80% [4]), and gen-
ome-wide association studies (GWAS) have revealed[40
common-variant loci associated with CD; the strongest
associated with the human leukocyte antigen (HLA) genes,
which lie in the major histocompatibility complex (MCH)
[5]. In contrast, in ALS, which has a heritability of *65%
[6], GWAS revealed a total of 7 loci [7]. Despite these dis-
tinct architectures, overlap between immune-regulated and
neurological disease is not unheard of: CD can present with
neurological symptoms [8–13], and frontotemporal demen-
tia, which has several risk loci that overlap with those of ALS
[14], shows an additional risk variant in the MHC [15].
If CD and ALS are causally related, one can expect a
significant overlap in genetic architectures; methods to
estimate this overlap are currently available [16, 17]. The
association between GS or CD and ALS may have impli-
cations for our understanding of a pathogenic mechanism,
as well as for future ALS treatment options. In this study,
therefore, we combined population-based case–control data
on gluten-related antibodies with medical history and
dietary information, and large-scale genetic data from
GWAS on CD and ALS, to examine the evidence for the
role of GS or CD in ALS etiology.
Methods
Study population
All participants in the serological and questionnaire studies
were included in the Prospective ALS study the
Netherlands (PAN) between 1 January 2006 and 31
December 2015 [18]. Patients were diagnosed according to
the revised El Escorial criteria [19]. The population-based
design of the PAN study was ensured by inclusion of
patients through multiple sources: neurologists, rehabilita-
tion physicians, the Dutch neuromuscular Patient Associ-
ation and our ALS website. Age- (±5 years) and gender-
matched controls were included through the general prac-
titioner of the participating patient. In the Netherlands,
every resident is registered at a general practitioner, which
makes the sample representative of the general population.
For genetic correlation analyses, we used data from a
GWAS of ALS, which included 12,577 sporadic ALS cases
and 23,475 unaffected controls, and a GWAS of CD, which
included 4533 patients and 10,750 controls. Both studies
comprised cohorts from Europe and the USA [7, 20].
Separately, ALS cases and population-matched controls
are being collected worldwide as part of Project MinE [21].
A subset of these samples is drawn from the neuromuscular
clinic at the University Medical Center Utrecht and con-
trols are selected from the PAN study to match cases by
geography, age and gender. Data collected on the samples
include disease status and genotyping on the Illumina 2.5M
array. As part of the Project MinE, samples and variants
have undergone quality control (detailed description in
Online Resource 1) [7].
Serological testing
In 359 population-based patients and 359 matched controls,
we measured TG6 antibody concentrations using the
ELISA IgA kit (Zedira, Darmstadt, Germany). TG6 posi-
tivity was calculated using the mean of the control group
(17.33 U/mL) plus 2 standard deviations (2 9 19.59
U/mL), and was set at 56.51 U/mL. In a subset of 199
patients and 199 controls, antibodies to TG2 were mea-
sured using the ELiA Celikey IgA kit (Phadia AB, Upp-
sala, Sweden). Serum samples containing a TG2 antibody
titer of more than 10 U/mL were considered positive, as
recommended by the manufacturer. In the same subset, we
determined the prevalence of IgA class endomysial anti-
bodies (EMA) using indirect immunofluorescence (Biog-
nost, Heule, Belgium). Total IgA was measured, and a
serum IgA concentration below 0.05 g/L was regarded as
IgA deficiency. Gluten-associated antibodies were com-
pared between groups using Student’s t test for antibody
concentrations and the Chi-square test for comparison of
the seroprevalence, or Fisher’s exact test in case of cell
counts below five. Due to low numbers, we were unable to
test for interaction with gender using an interaction term in
a logistic model; instead, we stratified according to gender.
We compared antibody levels and positivity between bul-
bar and spinal patients, and antibody measures in patients
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with a time to diagnosis within the first quartile (repre-
senting patients with a rapid disease course) with controls.
Clinical characteristics between groups were compared
using the Mann–Whitney U test for continuous character-
istics; the Chi square for categorical characteristics (or
Fisher’s exact test as appropriate); the Cox proportional
hazard model for survival.
Medical history and gluten-free diet
We examined a structured questionnaire collected from
1829 population-based ALS patients and 3920 matched
controls to collect medical histories [18]. For patients, we
analyzed data referring to the period before symptom onset.
In addition, in the 199-item food frequency questionnaire,
participants were asked about their adherence to a specific
diet [22]. For patients, this was defined as the 1-month
period before symptom onset. All questionnaires were
checked for missing data or inconsistencies, and partici-
pants were contacted by telephone to complete or correct
the data. The survival status of patients was obtained by
checking the municipal population register and/or con-
tacting the general practitioner every 3 months. Propor-
tions of participants with CD or a GFD were compared
using the Fisher’s exact test because of the small numbers.
Genetic correlation using LD score regression
Correlations in genetic architectures between two traits can
provide insight into potential overlapping etiology between
diseases and may help disentangle shared potential causal
mechanisms [17]. To estimate the genome-wide genetic
correlation between ALS and CD, we used Linkage Dise-
quilibrium Score Regression (LDSC). In short, LDSC
considers the fact that, for polygenic traits, the association
signal at a single-nucleotide polymorphism (SNP) will also
capture information for SNPs nearby in linkage disequi-
librium. This relationship between linkage disequilibrium
and association signal can also be used to test for rela-
tionships between two traits at all SNPs across the genome.
A GWAS of ALS had been performed using a linear mixed
model (LMM) implemented in the Genome-Wide Complex
Trait Analysis (GCTA) software [7, 23], from which the
summary statistics for 1,217,311 SNPs were available [7].
Summary statistics for 499,513 SNPs from the CD GWAS
were obtained via personal communication with the
authors. Details of the statistical LDSC analysis are pro-
vided in the Online Resource 2.
Genetic correlation using genetic risk scores
We constructed a genetic risk score from associated CD
SNPs, to see if such a score could help predict ALS disease
status. We downloaded all SNPs associated by GWAS to
CD at p\ 1 9 10-6 from the NHGRI GWAS Database
[24]; data downloaded included SNP rsID, chromosome,
position, risk allele, P value, and reported odds ratio from
the GWAS. A total of 31 SNPs had complete information.
For duplicate SNPs, we kept the SNP results from the study
with the largest sample size. We extracted the genotypes
for these SNPs from 2833 unrelated Dutch samples (1823
cases and 1010 controls) that had been genotyped on the
Illumina 2.5 M array as part of Project MinE. A total of 21
SNPs were found in the genotyping data. We LD-pruned
the SNPs (r2\ 0.05) to ensure that all SNPs represented
independent associations to CD; LD pruning removed two
SNPs. We used the genotypes for the remaining 19 SNPs to
construct a genetic risk score by weighting the genotypes
by the odds ratio reported in the CD GWAS and summing
across all weighted genotypes (performed in Plink). We
used logistic regression to test for association between ALS
disease status and CD-based genetic risk score, correcting
for ten principal components and gender.
HLA association testing
The same 2833 unrelated Dutch samples from Project
MinE were used to perform imputation of the MHC. MHC
genotypes (build hg19, chromosome 6, positions
24,092,021–38,892,022) for these samples were extracted
from genotypes generated using the Illumina 2.5 M geno-
typing array. Details on sample quality checks and impu-
tation of the MHC genotypes are provided in the Online
Resource 3. When imputation was complete, we performed
QC, removing any sample with[2.5 alleles at any HLA
allele (Online Resource 3). We used the resulting genotype
dosages in 1786 ALS cases and 999 controls to perform
association testing between ALS status and four CD-as-
sociated HLA alleles: HLA-DQA1*0501, HLA-
DQB1*0201, HLA-DQB1*0202, and HLA-DQB1*0302.
We adjusted for ten principal components and gender. The
fifth HLA allele of interest, HLA-DQA1*0505, could not
be tested as it was absent from the SNP2HLA imputation
reference panel.
Results
Serological testing
We tested TG6 antibody levels in 359 patients and 359
controls, matched for baseline characteristics (Table 1).
The subgroup of 199 patients and 199 controls with mea-
sured TG2 antibody and EMA levels were also character-
istic-matched (data not shown). None of the patients was
IgA deficient. TG2 positivity ([10 U/mL) was found in one
696 J Neurol (2017) 264:694–700
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patient and zero controls. This patient was also the only
participant who tested positive for EMA, and was one of
the eleven patients with positive antibodies to TG6. Despite
having TG2, EMA and TG6 antibodies, this patient had
clinical characteristics (probable ALS, bulbar onset at the
age of 66 years) and a survival (1.33 years from onset)
compatible with typical ALS. Furthermore, routine blood
tests were normal, indicated no anemia, and magnetic
resonance imaging (MRI) revealed no white matter lesions.
Patients and controls had comparable TG6 antibody
concentrations (Student’s t test p = 0.66, Table 2) and
positivity for TG6 antibodies [11 patients (3.1%) and 12
controls (3.3%), Chi-square test p[ 0.99]. Stratifying by
gender did not reveal a difference in antibody concentra-
tions or prevalence (Student’s/Fisher’s test all p[ 0.48,
data not shown). Clinical characteristics of the 11
seropositive patients were similar to those of the 348
seronegative patients (Table 3). Eighty-one patients with a
short time to diagnosis (defined as\6 months and used as
a surrogate variable for a rapid disease course) had TG6
antibody levels similar to controls [mean (SD): 21.16
(31.56) vs. 17.33 (19.59), Student’s p = 0.30]. Two of the
81 patients (2.5%) tested positive for TG6 antibodies
(Fisher’s p[ 0.99; data not shown). Similarly, bulbar and
spinal patients had comparable TG6 antibody levels [mean
(SD): 17.53 (27.37) vs. 18.30 (20.20), Student’s p = 0.79]
and positivity [n (%): 3 (2.5%) vs. 8 (3.4%), Fisher’s
p = 0.76; data not shown].
Medical history and gluten-free diet
Questionnaire-derived data of 1829 ALS patients and 3920
controls showed they had similar characteristics (Table 1).
According to the data, 3 of 1829 ALS patients (0.16%) and
4 of 3920 controls (0.10%) had been diagnosed with CD
(Fisher’s p = 0.69). 1470 of these 1829 patients and 3683
of the 3920 controls filled in a food frequency question-
naire; in addition to the 3 patients and 4 controls with a
medical history of CD, we identified 2 more patients
(n = 5 in total; 0.3%) and 8 controls (n = 12 in total;
0.3%) who were following a GFD prior to disease onset
(Fisher’s p[ 0.99). Table 4 shows the clinical character-
istics and disease course of the 5 patients who adhered to a
GFD. On average, their survival after disease onset was
3.3 years, consistent with standard ALS disease
progression.
Genetic correlation between ALS and CD
We applied LDSC analysis using summary-level results
from a GWAS of ALS (12,577 cases and 23,475 controls)
and of CD (4533 CD cases and 10,750 controls). The
genetic correlation between ALS and CD was 0.06 (stan-
dard error = 0.07; p = 0.37), indicating that, genome-
wide, there was no evidence for genetic correlation
between the traits. While LDSC looks for trait correlation,
genetic risk scores can be used to test for association
between two traits at specific loci. We tested a genetic risk
score based on CD loci in the Dutch Project MinE samples,
including 1823 ALS cases and 1010 matched controls. The
score was not associated with ALS disease status
(p = 0.47).
Association testing at HLA alleles
We performed HLA imputation and association analysis in
the same Project MinE Dutch ALS patients and controls.
After additional QC of the data, we found no association at
Table 1 Baseline characteristics
Serological cohort Population-based cohort
Patients (n = 359) Controls (n = 359) Patients (n = 1829)b Controls (n = 3920)
Male, n (%) 231 (64.3) 217 (60.4) 1096 (59.9) 2334 (59.5)
Age (year), median (range)a 64.6 (23.5–87.8) 63.9 (20.4–83.9) 62.8 (23.1–87.9) 63.8 (17.5–91.9)
Age at diagnosis (year), median (range) 65.5 (23.8–88.7) 64.2 (23.8–88.9)
Bulbar onset, N (%) 122 (34.0) 574 (32.2)
El Escorial criteria, N (%)
Definite 72 (20.1) 323 (18.4)
Probable 127 (35.4) 724 (41.3)
Laboratory-supported probable 105 (29.2) 324 (18.5)
Possible 55 (15.3) 383 (21.8)
a Age at onset for patients; age at inclusion for controls
b Missing data in patients: age 54 (3.0%); age at diagnosis 17 (0.9%); site of onset 49 (2.7%); El Escorial criteria 75 (4.1%) of patients. No
missing data in controls or in the serological cohort
J Neurol (2017) 264:694–700 697
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any of the four HLA alleles associated with CD in 1786
ALS cases and 999 controls (all p[ 0.28, Table 5).
Discussion
In this study, we combined serological, epidemiological
and genetic data to examine whether GS or CD is associ-
ated with ALS risk. Although we cannot rule out CD in our
patient with gluten-related antibodies without performing a
small intestine biopsy (gold standard [9]), CD is highly
unlikely since blood tests did not indicate anemia [8, 9],
brain MRI did not show white matter changes [10–12], and
the patient had typical ALS symptoms and disease course.
Moreover, whereas our patient experienced speech diffi-
culties, previous case reports do not describe bulbar
symptoms in gluten-related ALS mimic syndromes
[10–13]. Furthermore, combining two large GWAS
revealed no genetic correlation between CD and ALS,
either genome-wide or through a targeted approach. HLA
alleles in the MHC shown to be associated with CD
showed no association with ALS disease status. In addition,
we found no difference in concentrations or positivity of
gluten-related TG6 antibody between patients and controls.
Table 2 Serological results
Patients (n = 359) Controls (n = 359) p value
TG6 IgA, U/mL, mean (SD) 18.1 (22.9) 17.3 (19.6) 0.66
Positive TG6 IgA, n (%)a 11 (3.1) 12 (3.3) [0.99
a Cutoff is 56.51 U/mL
Table 3 Patient characteristics
of seropositive and seronegative
TG6 patients
Seropositive (n = 11) Seronegative (n = 348) p value
Male, n (%) 8 (72.7) 223 (64.1) 0.79
Age (year), median (range) 63.1 (45.1–73.5) 64.8 (23.5–87.8) 0.37
Age at diagnosis (year), median (range) 64.0 (47.1–82.5) 65.6 (23.8–88.7) 0.53
Bulbar onset, n (%) 3 (27.3) 119 (34.2) 0.76
Survival (year), median (range) 2.32 (1.17–6.10) 2.32 (0.41–6.76) 0.63
El Escorial criteria, n (%) 0.54
Definite 3 (27.3) 69 (19.8)
Probable 5 (45.5) 122 (35.1)
Laboratory-supported probable 1 (9.1) 104 (29.9)
Possible 2 (18.2) 53 (15.2)
Table 4 Patient characteristics of the five patients on a gluten-free diet
Patient Gender Site of onset Age at onset (year) Age at diagnosis (year) EEC Survivala (year)
1. Female Spinal 64.3 64.9 LSP 4.1
2. Female Spinal 55.2 56.1 Probable 3.3
3. Male Spinal 61.2 63.2 Definite 4.1
4. Male Spinal 49.4 49.8 LSP 3.5
5. Female Bulbar 64.7 65.1 Probable 1.6
EEC El Escorial criteria, LSP laboratory-supported probable
a All patients were deceased
Table 5 HLA allele
frequencies
Dutch ALS patients (n = 1786) Controls (n = 999) p value
HLA-DQA1*0501 (%) 25.9 27.1 0.28
HLA-DQB1*0201 (%) 14.4 15.6 0.34
HLA-DQB1*0202 (%) 7.2 6.6 0.61
HLA-DQB1*0302 (%) 10.0 9.4 0.44
698 J Neurol (2017) 264:694–700
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Patients with antibodies to TG6 or CD/GFD have charac-
teristics compatible with ALS and patients on a GFD did
not demonstrate prolonged survival time (average survival
3.3 years). In short, across this myriad of analyses, we
found no evidence for association or overlap between GS
or CD and ALS, and no evidence that initiation of a GFD in
ALS patients would be beneficial.
TG6 has been relatively recently added to the list of
gluten-related antibodies and, since then, has been descri-
bed in patients with idiopathic cerebellar ataxia,
myelopathy secondary to malabsorption, autoimmune
neuropathy and ALS [2, 25, 26]. Using the same ELISA kit
for TG6 antibodies as in this study, a previous study in
Israeli-descent samples showed 15.3% of the 150 referred
patients and 4.3% of the 115 controls to have elevated
levels of antibodies to TG6 [2]. In a larger study, we found
that 3.1% of 359 patients and 3.3% of 359 controls had
elevated levels of antibodies to TG6. The TG6 antibody
concentrations of the Israeli controls (21.0 U/mL) and the
Dutch controls (17.3 U/mL) were similar, but cutoff scores
for positivity differed: 42 U/mL in the study by Gadoth
et al. [2] and 56.51 U/mL in our study. This could explain
the slightly lower frequency of controls with elevated TG6
antibodies in our study. On the other hand, the TG6 anti-
body concentrations in patients in the Israel-based study [2]
(29.3 U/mL) seem to be higher compared to those in this
study (18.1 U/mL). One similarity between the two studies
is the prevalence of the CD-associated HLA risk alleles,
which were not different between patients and controls.
Thus, although the prevalence of CD in Israel does not
seem to be higher than in Europe [27], it might be that GS,
as measured by the presence of TG6 antibodies, occurs in a
subgroup of Israeli ALS patients and not in patients of
Dutch/European origin.
The CD prevalence of 0.10–0.16%, as reported by
questionnaires in our study, is lower than that of the
European population (around 1%) [8]. We expect, how-
ever, this bias to be non-differential between patients and
controls, i.e., not related to the presence of disease. In
addition, we did not see a difference between patients and
controls who are on a GFD as reported in the food fre-
quency questionnaire, a finding in line with a nationwide
record-linkage study by Ludvigsson et al., in which the
number of ALS diagnoses during follow-up among indi-
viduals diagnosed with CD via small intestinal biopsy was
similar to the number of ALS diagnoses in the general
Swedish population [28]. Using the same study design as
Ludvigsson et al., Turner et al. found higher than expected
numbers of ALS patients among groups of individuals with
various autoimmune diseases, one of which was CD [1].
This finding contradicts the study by Seelen et al. in which
no prevalence difference of autoimmune diseases was
found between cases and controls [29].
CD is triggered upon exposure to gluten. In this study,
we chose to investigate IgA class antibodies specifically, as
gluten-related serology tests for TG2 and EMA are usually
IgA based and the previous study on TG6 antibodies in
relation to ALS showed IgA, as opposed to IgG class
antibodies, to be relevant [2, 9]. Based on positive asso-
ciations published in case reports, a previous study sug-
gested including serological tests for GS or CD in the
diagnostic workup for ALS [10]. The results of our study
reveal that there is no indication for initiating a GFD in
patients who have positive antibody tests for TG6, TG2 or
EMA and typical ALS without features of CD, such as
anemia or MRI white matter changes. The diet can be
burdensome and limit quality of life [30, 31], a heavy price
to pay for a patient with a fatal disease. Moreover, a phase
2 trial demonstrated the benefits of a high-calorie diet in
ALS patients [32], something that might be difficult to
achieve with a GFD.
In the present relatively large case–control study, we
found no serological evidence for involvement of gluten-
related antibodies in ALS etiology. We did not observe an
association between CD and ALS in either medical history
or genetic data analysis. These findings indicate that, in our
data, there is no evidence for a causal relationship between
GS or CD and ALS, and, therefore, it is unlikely that there
is a role for a GFD in the treatment of ALS.
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